Vaccinex, Inc. (VCNX): Price and Financial Metrics


Vaccinex, Inc. (VCNX): $1.16

0.03 (+2.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VCNX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VCNX Stock Summary

  • VCNX's price/sales ratio is 45.86; that's higher than the P/S ratio of 95.95% of US stocks.
  • VCNX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.61% of US stocks.
  • With a year-over-year growth in debt of -87.43%, Vaccinex Inc's debt growth rate surpasses only 2.34% of about US stocks.
  • Stocks that are quantitatively similar to VCNX, based on their financial statements, market capitalization, and price volatility, are VNE, SNGX, HIMX, ORGS, and ERYP.
  • Visit VCNX's SEC page to see the company's official filings. To visit the company's web site, go to www.vaccinex.com.

VCNX Valuation Summary

  • In comparison to the median Healthcare stock, VCNX's price/sales ratio is 1218.42% higher, now standing at 50.1.
  • Over the past 37 months, VCNX's EV/EBIT ratio has gone up 3.9.
  • VCNX's price/sales ratio has moved down 259.4 over the prior 37 months.

Below are key valuation metrics over time for VCNX.

Stock Date P/S P/B P/E EV/EBIT
VCNX 2021-08-31 50.1 4.4 -2.7 -2.1
VCNX 2021-08-30 48.5 4.2 -2.6 -2.0
VCNX 2021-08-27 50.1 4.4 -2.7 -2.1
VCNX 2021-08-26 51.0 4.4 -2.7 -2.1
VCNX 2021-08-25 49.1 4.3 -2.6 -2.0
VCNX 2021-08-24 49.5 4.3 -2.6 -2.0

VCNX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VCNX has a Quality Grade of D, ranking ahead of 11.88% of graded US stocks.
  • VCNX's asset turnover comes in at 0.069 -- ranking 295th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows VCNX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.069 0.999 12.119
2021-03-31 0.092 0.999 9.215
2020-12-31 0.065 0.997 8.045
2020-09-30 0.080 0.997 7.020
2020-06-30 0.069 0.980 6.213
2020-03-31 0.063 0.944 5.545

VCNX Price Target

For more insight on analysts targets of VCNX, see our VCNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.00 Average Broker Recommendation 1 (Strong Buy)

VCNX Stock Price Chart Interactive Chart >

Price chart for VCNX

VCNX Price/Volume Stats

Current price $1.16 52-week high $3.28
Prev. close $1.13 52-week low $0.90
Day low $1.07 Volume 139,300
Day high $1.20 Avg. volume 846,953
50-day MA $1.28 Dividend yield N/A
200-day MA $1.61 Market Cap 49.49M

Vaccinex, Inc. (VCNX) Company Bio


Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington’s disease. The company’s preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is based in Rochester, New York.


VCNX Latest News Stream


Event/Time News Detail
Loading, please wait...

VCNX Latest Social Stream


Loading social stream, please wait...

View Full VCNX Social Stream

Latest VCNX News From Around the Web

Below are the latest news stories about Vaccinex Inc that investors may wish to consider to help them evaluate VCNX as an investment opportunity.

Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting

Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wednesday, March 2, 2022ROCHESTER, N.Y., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that a poster will be presented at the 17th Annual HD Therapeutics Conference (hosted by CHDI Foundation) with its collaborator, Dr.

Yahoo | February 24, 2022

With stock up 25%, Insiders of Vaccinex, Inc. (NASDAQ:VCNX) must be wishing they had bought more last year

Vaccinex, Inc. ( NASDAQ:VCNX ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...

Yahoo | February 11, 2022

Vaccinex''s CEO, Chairman To Inject $4M To Fund The Lead Program

Vaccinex Inc (NASDAQ: VCNX ) has announced a private placement of approximately 5.9 million at $1.11 per share for about $6.6 million gross proceeds . The private placement is expected to close on January 31. Participants in the private placement include entities controlled by Maurice Zauderer, President & CEO of Vaccinex, and Albert Friedberg, Vaccinex''s Chairman. Each of them has purchased $2 … Full story available on Benzinga.com

Benzinga | January 28, 2022

Vaccinex's CEO, Chairman To Inject $4M To Fund The Lead Program

Vaccinex Inc (NASDAQ: VCNX) has announced a private placement of approximately 5.9 million at $1.11 per share for about .6 million gross proceeds. The private placement is expected to close on January 31. Participants in the private placement include entities controlled by Maurice Zauderer, President & CEO of Vaccinex, and Albert Friedberg, Vaccinex's Chairman. Each of them has purchased $2 million worth of shares. Other investors include an entity controlled by Jacob Frieberg, another board mem

Yahoo | January 28, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | January 27, 2022

Read More 'VCNX' Stories Here

VCNX Price Returns

1-mo -7.20%
3-mo -10.77%
6-mo N/A
1-year -48.21%
3-year -81.90%
5-year N/A
YTD 11.54%
2021 -49.76%
2020 -57.32%
2019 33.06%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7119 seconds.